588668 Disclosed is the use of helicin and its derivatives selected from 4,6-0-benzylidine-D-glucopyranosyloxy, 2-ß-D-glucopyranosyloxy benzaldehyde, 3-ß-D-glucopyranosyloxy benzaldehyde, or 4-ß-D-glucopyranosyloxy benzaldehyde in the preparation of a medicament for treatment of cancer, and wherein the medicament may further comprise a secondary agent selected from azacitidine, bevacizumab, bortezomib, capecitabine, cetuximab, clofarabine, dasatinib, decitabine, docetaxel, emend, erlotinib hydrochloride, exemestane, fulvestrant, gefitinib, gemcitabine hydrochloride, imatinib mesylate, imiquimod, lenalidomide, letrozole , nelarabine, oxaliplatin, paclitaxel, paclitaxel albumin-stabilized nanoparticle formulation, palifermin, panitumumab, pegaspargase, pemetrexed disodium, rituximab, sorafenib tosylate, sunitinib malate, tamoxifen citrate, targretin, temozolomide, or thalidomide.
